Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers

Gynecologic Oncology

Volumn 123, Issue 2, 2011, Pages 196-199

  Hyman, David M ^a   Zhou, Qin ^a   Arnold, Angela G ^a   Grisham, Rachel N ^a   Iasonos, Alexia ^a   Kauff, Noah D ^a   Spriggs, David ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BRCA; Ovarian cancer; Topoisomerase I inhibitors; Topotecan

Indexed keywords

BRCA1 PROTEIN; PLATINUM; TOPOTECAN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PERITONEUM CANCER; PHYSICIAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

ADULT; AGED; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PLATINUM; RETROSPECTIVE STUDIES; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 80054770585     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.07.019     Document Type: Article

References (22)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. T. Pal, J. Permuth-Wey, and J.A. Betts BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases Cancer 104 2005 2807 2816
3. H.A. Risch, J.R. McLaughlin, and D.E. Cole Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer Am J Hum Genet 68 2001 700 710
4. M.S. Brose, T.R. Rebbeck, K.A. Calzone, J.E. Stopfer, K.L. Nathanson, and B.L. Weber Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program J Natl Cancer Inst 94 2002 1365 1372
5. D. Ford, D.F. Easton, and M. Stratton Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium Am J Hum Genet 62 1998 676 689
6. N.D. Kauff, J.M. Satagopan, and M.E. Robson Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 346 2002 1609 1615
7. T.R. Rebbeck, H.T. Lynch, and S.L. Neuhausen Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl J Med 346 2002 1616 1622
8. A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman, and S. Sadetzki Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer J Clin Oncol 26 2008 20 25
9. Y. Ben David, A. Chetrit, and G. Hirsh-Yechezkel Effect of BRCA mutations on the length of survival in epithelial ovarian tumors J Clin Oncol 20 2002 463 466
10. A. Husain, G. He, E.S. Venkatraman, and D.R. Spriggs BRCA1 up-regulation is associated with repair-mediated resistance to cis- diamminedichloroplatinum(II) Cancer Res 58 1998 1120 1123
11. H. Farmer, N. McCabe, and C.J. Lord Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
12. D.S. Tan, C. Rothermundt, and K. Thomas "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations J Clin Oncol 26 2008 5530 5536
13. D.J. Gallagher, J.A. Konner, and K.M. Bell-McGuinn Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity Ann Oncol 22 2011 1127 1132
14. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322
15. T.J. Herzog, M.W. Sill, and J.L. Walker A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study (GOG 146Q) Gynecol Oncol 120 2011 454 458
16. J. Sehouli, D. Stengel, and P. Harter Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the north-eastern German society of gynecological oncology ovarian cancer study group J Clin Oncol 29 2011 242 248
17. Y. Pommier Topoisomerase I inhibitors: camptothecins and beyond Nat Rev Cancer 6 2006 789 802
18. Y. Pommier, E. Leo, H. Zhang, and C. Marchand DNA topoisomerases and their poisoning by anticancer and antibacterial drugs Chem Biol 17 2010 421 433
19. G.J. Rustin, M. Quinn, and T. Thigpen Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) J Natl Cancer Inst 96 2004 487 488
20. W. Sakai, E.M. Swisher, and B.Y. Karlan Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers Nature 451 2008 1116 1120
21. S.L. Edwards, R. Brough, and C.J. Lord Resistance to therapy caused by intragenic deletion in BRCA2 Nature 451 2008 1111 1115
22. S.A. Zander, A. Kersbergen, and E. van der Burg Sensitivity and acquired resistance of BRCA1; p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan Cancer Res 70 2010 1700 1710